Where Is the Line?

September 16, 2026 By The Editor, Connecticut CannaTimes

Connecticut’s cannabis industry isn’t hiding its relationship with state government.

It puts it on plaques.

In 2024, the Connecticut Cannabis Chamber of Commerce named State Sen. James Maroney its “Legislator of the Year.”

Maroney wasn’t the only public official honored.

State Rep. Marcus Brown was named Community Impact Leader of the Year.

Rod Marriott, director of the Drug Control Division at the Connecticut Department of Consumer Protection, was named “Regulator of the Year.”

And alongside those government officials, the Chamber honored members of the industry itself: Fine Fettle’s Kennard Ray as Industry Collaborator of the Year, Affinity Grow as Cultivator of the Year and Budr as Dispensary of the Year.

The event was advertised as bringing DCP Commissioner Bryan Cafferelli, Social Equity Council leadership, legislators, mayors and cannabis industry leaders together under one roof.

Look at that arrangement for a moment.

The regulated.

The regulators.

And the lawmakers who write the laws governing the regulated.

All participating in an event organized by an industry trade association.

Is that illegal?

We have found no evidence that it is.

Does receiving an award establish bribery, corruption or a quid pro quo?

Absolutely not.

But those aren’t the only questions Connecticut should be willing to ask.

Where is the line?

And perhaps more importantly:

Does Connecticut have a meaningful one when it comes to the relationship between the cannabis industry and the government responsible for writing and administering its laws?

THE CHAMBER DIDN’T HIDE WHY IT HONORED MARONEY

The Connecticut Cannabis Chamber announced Maroney’s award publicly.

Its announcement didn’t merely recognize him as a supportive legislator. The Chamber praised his work as General Law chairman and his role in developing what it called the industry’s “legislative backbone.”

That is an extraordinary phrase.

Not because it proves wrongdoing.

It doesn’t.

But General Law isn’t a ceremonial committee.

It has jurisdiction over the Department of Consumer Protection and plays a central role in shaping Connecticut’s cannabis laws.

And Maroney is its Senate co-chair.

The Chamber, meanwhile, isn’t merely a networking club.

Today, it openly describes its advocacy operation as including a “dedicated legislative lobbying team” whose work is intended to ensure policymakers hear directly from businesses, workers and communities affected by cannabis regulation.

There is nothing clandestine about any of this.

In fact, that’s the point.

“WE HAVE BEEN IN DIALOGUE … FOR MONTHS”

If Connecticut residents want to understand how organized cannabis interests participate in the legislative process, they don’t need leaked emails or secret recordings.

They can read the Chamber’s own testimony.

In written testimony submitted to General Law in 2025, the Connecticut Cannabis Chamber told committee leadership:

“We have been in dialogue with the leadership of the General Law Committee for months now.”

The Chamber thanked leadership for hearing the industry’s concerns and said it understood additional revisions to the proposed legislation would reflect that dialogue.

Let’s be clear.

That’s lobbying.

Lobbying is legal.

Businesses affected by legislation have every right to tell lawmakers what they believe legislation should say.

Legislators should understand the industries they regulate.

But let’s also stop pretending that access stops mattering merely because access is lawful.

The organization representing cannabis businesses said publicly that it had spent months in dialogue with the leadership of the committee responsible for major cannabis legislation.

Fine.

Then Connecticut should answer another question.

When was the last time medical cannabis patients got months?

Not three minutes at a microphone.

Not an email attachment.

Not a public hearing after a bill has already been drafted.

Months of substantive dialogue with committee leadership while cannabis policy is being developed.

Maybe those conversations happened.

If so, we’d like to document them.

Who participated?

What patient legislation was discussed?

What changes resulted?

Because that’s the comparison that matters.

THE INDUSTRY BUILT A SEAT AT THE TABLE

None of this should really be considered criticism of the Cannabis Chamber for doing what a trade association exists to do.

It organized.

It developed relationships.

It hired people who understand government.

It created a lobbying operation.

It brings businesses together to identify common policy priorities.

It communicates those priorities to legislators.

And it attempts to get them enacted.

In fact, testimony at the March 4, 2026 General Law hearing provides an unusually candid glimpse of that process.

Chamber Executive Director Nicole Burns told legislators that after the previous session she spent months talking with owners, cultivators, retailers, Chamber members and nonmembers about what the industry needed.

The objective was straightforward: identify common problems and work collectively toward policy changes that would make the industry stronger.

Again:

That’s what an effective trade association does.

The question isn’t why cannabis businesses organized effectively.

The question is:

Where is the equivalent institutional power for patients?

PATIENTS CAN GET INTO THE BUILDING. CAN THEIR BILLS GET OUT?

In 2025, lawmakers proposed HB 5429, An Act Concerning Caregivers, Qualifying Patients and the Palliative Use of Cannabis.

It was explicitly about Connecticut’s medical cannabis program.

The proposal addressed qualifying patients and caregivers and sought significant changes to Connecticut’s caregiver and cultivation framework.

It received a public hearing on February 14, 2025.

And then it stopped.

It never became law.

It did not advance out of committee.

There was no final substantive committee vote approving or rejecting the proposal.

That distinction matters.

Because when legislation quietly stops moving, nobody necessarily has to say:

I oppose this.

Nobody necessarily has to identify:

Here is the provision I cannot accept.

Nobody necessarily has to put their name next to:

No.

The legislation simply becomes another dead bill.

Connecticut patients can apparently get into the Legislative Office Building.

The harder question is whether their proposals can get out.

A BILL FOR TERMINALLY ILL PATIENTS GOT A HEARING. THEN IT STALLED.

Consider HB 5242 this year.

The Public Health Committee raised legislation concerning medical cannabis use by terminally ill qualifying patients in certain healthcare facilities.

The bill would have required covered facilities to permit qualifying terminally ill patients to use cannabis subject to restrictions, including prohibitions on smoking and vaping and requirements governing storage and facility procedures.

It received a public hearing on February 23.

The committee subsequently placed HB 5242 on its March 2 agenda with a proposed Joint Favorable recommendation to the floor.

Yet the legislation ultimately did not advance.

There were substantive objections to the proposal, including concerns involving healthcare facilities and federal requirements. Those concerns deserve to be reported and evaluated on their merits.

But zoom out.

Caregiver reform?

Hearing. No advancement out of committee.

Medical cannabis access for terminally ill patients?

Hearing. Proposed favorable action. No ultimate advancement.

Meanwhile Connecticut continues finding legislative bandwidth for extraordinarily complicated questions involving the commercial cannabis marketplace.

That does not prove corruption.

It does justify asking what Connecticut’s cannabis-policy priorities actually are.

NOW LOOK AT WHAT HAPPENS WHEN A BIG CANNABIS BILL MOVES

In 2026, General Law raised HB 5350, An Act Concerning Cannabis, Hemp and Infused Beverage Regulation.

This was no tiny technical correction.

The legislation dealt with out-of-state medical patients, cannabis business credit, pharmacist requirements, THC limits, remediation, packaging, laboratory testing, infused beverages, licensing, regulatory policy and numerous other subjects.

General Law held its public hearing on March 4.

Twelve days later, on March 16:

Joint Favorable Substitute.

The legislation continued moving.

It passed the House.

It passed the Senate.

And on May 20, Gov. Ned Lamont signed it.

HB 5350 became Public Act 26-8.

None of that establishes that the Connecticut Cannabis Chamber controlled the legislation.

It doesn’t establish that industry got everything it requested.

It didn’t.

But it establishes something simpler:

Connecticut knows how to move cannabis legislation when sufficient legislative support exists to move it.

Patients are entitled to ask why proposals centered primarily on their interests so often have a harder journey.

MAYBE WE’RE ASKING THE WRONG QUESTION

It would be easy to look at photographs of politicians smiling beside cannabis executives and decide something sinister must be happening.

That would also be intellectually lazy.

Connecticut Canna Times has found no evidence that Sen. Maroney traded official action for an award, a meal or anything else.

We’ve found no evidence that Rod Marriott changed a regulatory decision because the Chamber named him Regulator of the Year.

And a photograph of a politician standing beside cannabis executives proves little beyond the fact that they stood together for a photograph.

So dispense with the cheap allegation.

Here’s the harder question:

What if none of this needs to be corrupt to produce an unhealthy imbalance?

What if the advantage isn’t a secret envelope?

What if it’s access?

Organization.

Professional government affairs.

Institutional relationships.

The ability to spend months discussing legislation with committee leadership.

The ability to know which provision is negotiable.

The ability to organize owners, cultivators and retailers before legislation reaches a public hearing.

The ability to come back year after year as an institution rather than as one sick patient allotted three minutes before a legislative committee.

That’s not bribery.

It’s power.

And power deserves scrutiny even when it is exercised entirely within the law.

LEGISLATOR OF THE YEAR. REGULATOR OF THE YEAR.

Return to those awards.

Legislator of the Year.

Regulator of the Year.

Those titles raise questions that Connecticut should be comfortable answering.

What exactly does an industry trade association value when selecting its Legislator of the Year?

What does it value when selecting its Regulator of the Year?

Who makes those selections?

What are the criteria?

What interaction occurs between the organization and those officials before and after those awards?

There may be completely ordinary answers to every question.

Then answer them.

Transparency shouldn’t be frightening if the relationships are appropriate.

AND NOW ANOTHER CHAMBER LUNCH

A flyer supplied to Connecticut Canna Times advertises another Connecticut Cannabis Chamber event for September 29, 2026, at The August at Steelpointe Harbor in Bridgeport.

It advertises lunch.

It says:

FOR MEMBERS.

And its special guest is listed as:

Sen. James Maroney — General Law Committee Co-Chair.

Connecticut Canna Times has not independently located that particular event on the Chamber’s current online event calendar as of publication, so we are describing precisely what the flyer represents rather than independently asserting additional details about the event.

If authentic, there is nothing inherently improper about Maroney attending.

In fact, here’s our position:

He should go.

Legislators should talk to business owners.

They should understand regulations that aren’t working.

They should hear from large companies.

They should hear from small companies.

They should hear from social-equity businesses.

They should hear from employees.

That’s part of legislating.

But there’s another half to that principle.

SENATOR MARONEY: GIVE THE PATIENTS THE SAME ROOM

Don’t stop meeting with the Cannabis Chamber.

Meet with patients, too.

Not another three-minute hearing slot.

Not another inbox.

Not another promise that someone will “take a look.”

Give Connecticut medical cannabis patients and caregivers a substantive opportunity to discuss legislation affecting them before the 2027 cannabis agenda is written.

Put the caregiver proposal on the table.

Go through it section by section.

If a plant limit creates a policy concern, identify it.

If allowing a cultivating caregiver to serve multiple patients raises diversion concerns, explain them.

If outdoor cultivation creates a public-safety problem, show the evidence.

If DCP needs different enforcement language, identify the problem.

If provisions need to change, debate those provisions.

That’s what legislating is supposed to be.

Patients aren’t asking lawmakers to stop listening to businesses.

They’re asking government to ensure that organized commercial access isn’t the only sophisticated access in the room.

WHERE IS THE LINE?

Maybe Connecticut doesn’t need a scandal.

Maybe it needs sunlight.

Perhaps Connecticut should require greater disclosure of substantive lobbying contacts involving pending legislation.

Perhaps industry-sponsored appearances by legislators and regulators should be easier for the public to identify.

Perhaps the public should be able to determine which outside organizations proposed language that ultimately appeared in major legislation.

Those are policy questions on which reasonable people can disagree.

But one principle should not be controversial:

The public shouldn’t have to guess who had a seat at the table when its laws were written.

The Connecticut Cannabis Chamber organized effectively.

It built relationships.

It created a lobbying operation.

It established itself as a recognized voice in Hartford.

It tells policymakers what its members need.

And policymakers listen to at least some of those requests.

That’s participation in government.

But Connecticut’s medical cannabis patients participate in this government too.

They don’t have corporate government-affairs departments.

They don’t have the Chamber’s resources.

They aren’t handing out Legislator of the Year and Regulator of the Year plaques.

And when their legislation stops moving, there isn’t an awards banquet explaining why.

So Connecticut Canna Times isn’t alleging a secret conspiracy.

We’re asking about something happening largely in public.

When an organization representing the regulated industry honors the people writing and administering its regulations; when that organization publicly describes months of dialogue with legislative leadership; and when patient-centered proposals struggle to make it through the legislative process—where exactly does Connecticut believe the line should be?

Maybe every relationship described here is completely appropriate.

If so, demonstrate that the door swings both ways.

Give the patients the same room.

Give them the same substantive conversation.

And when their legislation comes before the General Assembly:

Put the decision on the record.

— The Editor

Connecticut Canna Times